Lakefront Biotherapeutics (GLPGF) Profit After Tax (QoQ) (2016 - 2026)
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) Profit After Tax (QoQ) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.28 Bn | 197.29 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.28 Bn | 178.10 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.26 Bn | 124.41 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.58 Bn | 74.58 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.67 Bn | 56.48 Bn | 1.37 Bn |
| 6 | Moderna | 54.58 Bn | 49.44 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.01 Bn | 30.70 Bn | 992.69 Mn |
| 8 | Biogen | 31.26 Bn | 29.98 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.78 Bn | 29.78 Bn | 1.16 Mn |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -91.04% |
| Mar 31, 2026 | -100.00% |
| Dec 31, 2025 | 158,294.67% |
| Sep 30, 2025 | -97.82% |
| Jun 30, 2025 | 25.92% |
| Mar 31, 2025 | -100.20% |
| Dec 31, 2024 | 323,625.57% |
| Sep 30, 2024 | -18.40% |
| Jun 30, 2024 | -121.07% |
| Mar 31, 2024 | -99.96% |
| Dec 31, 2023 | 340,378.77% |
| Sep 30, 2023 | 301.33% |
| Jun 30, 2023 | -233.36% |
| Mar 31, 2023 | 111.78% |
| Dec 31, 2022 | -1,074.47% |
| Sep 30, 2022 | 206.85% |
| Jun 30, 2022 | -35.92% |
| Mar 31, 2022 | 76.24% |
| Dec 31, 2021 | 55.42% |
| Sep 30, 2021 | -82.06% |